News | April 04, 2007

The Verdict is Still Out on CAD for Mammo

April 5, 2007 - Controversy over the effectiveness of CAD for screening mammography mounted with recent findings from a study led by Joshua J. Fenton, M.D., M.P.H., on the influence of computer-aided detection (CAD) on the performance of screening mammography, which was published in the April 2007 issue of The New England Journal of Medicine (NEJM). Researchers found that the use of CAD was associated with reduced accuracy of interpretation of screening mammograms.

The study evaluated the association between the use of CAD at mammography facilities and the performance of screening mammography from 1998 through 2003 at 43 facilities in three states. With data collected from 222,135 women and 429,345 mammograms, researchers found that diagnostic specificity decreased from 90.2 percent before implementation to 87.2 percent after implementation, the positive predictive value also decreased from 4.1 percent to 3.2 percent and the rate of biopsy increased by 19.7 percent. Analyses of data from all 43 facilities showed that the use of CAD was associated with significantly lower overall accuracy than was non-use.

In an editorial commentary, published in the same issue of the Journal, Ferris M. Hall, M.D., acknowledged that while the study was �the most comprehensive study analysis of computer-aided detection in breast screening to date,� it was flawed due to the failure to assess the time required to adjust to CAD � the seven sites contributing CAD cases to the Fenton study had been using CAD for a time period ranging from 2 months to several years with an average amount of time in use of 7 months.

Related Content

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad Companion Chest CT,...
Telerad Tech Launches MammoAssist AI Software
Technology | Computer-Aided Detection Software | January 25, 2019
Telerad Tech recently announced the launch of MammoAssist, a new artificial intelligence (AI) product to analyze and...
Videos | Artificial Intelligence | December 13, 2018
ITN Editor Dave Fornell and ITN Contributing Editor Greg Freiherr share their insights on the vendors showing...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...